肝细胞癌的临床诊治：从指南到临床实践

王涛; 陈东风

doi:10.3969/j.issn.1001-5256.2021.08.001

肝细胞癌的临床诊治：从指南到临床实践

DOI: 10.3969/j.issn.1001-5256.2021.08.001

王涛,
陈东风^,

陆军军医大学大坪医院消化内科，重庆 400042

基金项目:

国家自然科学基金青年科学基金项目 (82002585);

重庆市自然科学基金面上项目 (cstc2020jcyj-msxmX0171)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：王涛负责检索文献，撰写论文；陈东风负责修改论文并校对。

详细信息

通信作者:
陈东风，chendf1981@126.com

中图分类号: R735.7
计量
- 文章访问数: 829
- HTML全文浏览量: 185
- PDF下载量: 271
- 被引次数: 0
出版历程
- 收稿日期: 2021-05-28
- 录用日期: 2021-05-28
- 出版日期: 2021-08-20

Clinical diagnosis and treatment of hepatocellular carcinoma: From guidelines to clinical practice

Tao WANG,
Dongfeng CHEN^,

Department of Gastroenterology, Daping Hospital, Army Medical University, Chongqing 400042, China

Research funding:

National Natural Science Foundation of China Young Scientist Fund (82002585);

General Project of Chongqing Natural Science Foundation (cstc2020jcyj-msxmX0171)

摘要

摘要: 肝细胞癌(HCC)发病隐匿，进展速度快，治疗效果差，是严重危害人民健康的常见恶性肿瘤。因此，国内外众多学术研究团体针对HCC筛查、诊断、治疗等方面的关键问题，发布了基于循证医学证据的多项肝癌诊治指南并不断进行更新。临床医生需在结合自身专业背景的基础上，对指南进行全面学习，以提高对肝癌领域相关进展的认识，进一步提高HCC患者的治疗效果。
- 癌, 肝细胞 /
- 诊断 /
- 综合疗法
Abstract: Hepatocellular carcinoma (HCC), characterized by insidious onset, rapid progression, and poor treatment outcome, is a common malignant tumor that seriously affects the health of people. Therefore, various academic research associations in China and globally have released a number of evidence-based medicine guidelines for liver cancer, focusing on the key issues in the screening, diagnosis, and treatment of HCC, and made constant updates to these guidelines. Clinicians are recommended to comprehend these guidelines with reference to their own specialties, so as to gain a better understanding of the advances in the field of liver cancer and further improve the prognosis of HCC patients.
- Carcinoma, Hepatocellular /
- Diagnosis /
- Combined Modality Therapy

HTML全文

参考文献(13)

[1]	CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
[2]	GORDAN JD, KENNEDY EB, ABOU-ALFA GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline[J]. J Clin Oncol, 2020, 38(36): 4317-4345. DOI: 10.1200/JCO.20.02672.
[3]	Bureau of Medical AdministrationNational Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007. 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
[4]	ZHOU J, YU L, GAO X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29(36): 4781-4788. DOI: 10.1200/JCO.2011.38.2697.
[5]	SUN YF, XU Y, YANG XR, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection[J]. Hepatology, 2013, 57(4): 1458-1468. DOI: 10.1002/hep.26151.
[6]	QU C, WANG Y, WANG P, et al. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy[J]. Proc Natl Acad Sci U S A, 2019, 116(13): 6308-6312. DOI: 10.1073/pnas.1819799116.
[7]	Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines for the diagnosis and treatment of primary liver cancer (2020 edition)[M]. Beijing: People's Medical Publishing House, 2020. 中国临床肿瘤学会指南工作委员会. 原发性肝癌诊疗指南2020[M]. 北京: 人民卫生出版社, 2020.
[8]	BI F, QIN S, GU S, et al. Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicentre phase Ⅱ/Ⅲ trial[C]. Chicago, 2020 ASCO Annual Meeting Symposium: abstract 4506.
[9]	YUAN GS, HE WM, HU XY, et al. Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study[J]. Chin J Hepatol, 2021, 29(4): 326-331. DOI: 10.3760/cma.j.cn501113-20210329-00148. 袁国盛, 何伟猛, 胡晓云, 等. 卡瑞利珠单克隆抗体联合阿帕替尼二线治疗不可切除肝细胞癌的临床疗效及安全性分析: 一项多中心回顾性研究[J]. 中华肝脏病杂志, 2021, 29(4): 326-331. DOI: 10.3760/cma.j.cn501113-20210329-00148.
[10]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
[11]	CALLEJA JL, CRESPO J, RINCÓN D, et al. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort[J]. J Hepatol, 2017, 66(6): 1138-1148. DOI: 10.1016/j.jhep.2017.01.028.
[12]	MARRERO JA, KULIK LM, SIRLIN CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 68(2): 723-750. DOI: 10.1002/hep.29913.
[13]	TANG A, BASHIR MR, CORWIN MT, et al. Evidence supporting LI-RADS major features for CT-and MR imaging-based diagnosis of hepatocellular carcinoma: A systematic review[J]. Radiology, 2018, 286(1): 29-48. DOI: 10.1148/radiol.2017170554.